Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain

4 Mar 2020

Abstract excerpt

As a non-antibody scaffold, monobodies based on the fibronectin type III (FN3) domain overcome antibody size and complexity while maintaining analogous binding loops. However, antibodies and their derivatives remain the gold standard for the design of new therapeutics. In response, clinical-stage therapeutic proteins based on the FN3 domain are beginning to use native fibronectin function as a point of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Monoclonal and Polyclonal Antibodies Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32143310
DOI: 10.3390/cells9030610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 DomainPMID 32143310Read ↗

Mutational and biophysical robustness in a prestabilized monobody.Semantic proximity Read ↗

Mutational and biophysical robustness in a pre-stabilized monobodySemantic proximity Read ↗

Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor twoSemantic proximity Read ↗

Antibody Structure and Function: The Basis for Engineering TherapeuticsSemantic proximity Read ↗

Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.Semantic proximity Read ↗

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeuticsSemantic proximity Read ↗

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-LifeSemantic proximity Read ↗

Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cellsSemantic proximity Read ↗

Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain.Semantic proximity Read ↗

Reliable repurposing of antibody interactome inside the cellSemantic proximity Read ↗

Stability engineering of the human antibody repertoireSemantic proximity Read ↗

Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.